Barclays Raises BMRN Price Target to $114

Barclays has reiterated its Overweight rating on BioMarin with a new price target of $114.0, a 109.02% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:29 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays raised its price target on BioMarin Pharmaceutical Inc. ($BMRN) to $114 from $111 on October 14, 2026, and rates the stock "Overweight".

Since the rating, $BMRN is down 0.8% to date (from the $55.14 close on Oct 14, 2026).

BMRN BioMarin Pharmaceutical Inc.

$54.68 -8.02% year to date

Daily close · Oct 16, 2026

Key Points

On October 14, 2026, Barclays reiterated its Overweight rating on BioMarin Pharmaceutical Inc. (BMRN) with a price target of $114.0, up from $111.0.
Barclays's $114 price target implies 109.02% upside from BioMarin Pharmaceutical Inc.'s ($BMRN) current $54.54 share price.
BioMarin shares are recently trading around $54.54, which is about 52.2% below the new target price.
The company is set to report its next earnings on October 26, 2026, following a year-over-year revenue growth of 19.9%.

Get $BMRN trade alerts by text

We text you when insiders, Congress or big funds trade $BMRN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BioMarin Pharmaceutical Inc. alert may contain errors. Disclosures

Barclays has reiterated its Overweight rating on BioMarin Pharmaceutical Inc. (BMRN) on October 14, 2026, raising its price target to $114.0 from a previous target of $111.0. This change reflects Barclays' ongoing positive outlook for the biotechnology company, which specializes in therapies for rare diseases.

Analyst rating track record

Barclays vs. the S&P 500

YTD return -0.09% hypothetical

All-time return -0.09% S&P 500 +0.37%

vs. S&P 500 -0.46% behind the index

Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in BioMarin

Several other institutional investors have also shown interest in BioMarin. Blackrock Inc. holds 20,445,212 shares valued at about $1.12 billion, having increased its stake by 626,278 shares, a 3.2% rise. Dodge & Cox Inc. has 14,844,930 shares worth approximately $811.7 million, growing its position by 282,511 shares, or 1.9%. Vanguard Capital Management LLC increased its holdings by 100,263 shares, ending with 8,743,633 shares valued at around $478.1 million, marking a 1.2% increase.

BioMarin Pharmaceutical Inc. Stock Down 14.7%

BioMarin shares are currently trading around $54.54, which is significantly below the new price target of $114.0 set by Barclays. This reflects a 52.2% discount compared to the target, indicating potential upside if the stock can recover. The shares are underperforming relative to the target, which could signal an opportunity for investors if the company meets its growth expectations.

12-month forecast

$BMRN price target

BioMarin Pharmaceutical Inc. daily closes and this analyst's $114 target. Not advice.

Recent Earnings

BioMarin reported a trailing twelve-month revenue of approximately $3.41 billion, with a net margin of 2.1% and a return on equity of 1.2%. The company has shown resilience with a year-over-year revenue growth of 19.9%. Investors are looking forward to the next earnings report scheduled for October 26, 2026, to see how these trends continue.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

F 30/100

Reported May 4, 2026

Forward outlook
6 target cuts vs 3 raises.
EPS & revenue
EPS missed estimates by 29.5%. Revenue missed estimates by 0.6%.
Profit surprise
EBITDA missed by 14 percent. Operating income missed by 23 percent.
Pre-earnings setup
Bar was high, analysts already very bullish.
Analyst signal
3 target raises, 6 target cuts.
Earnings quality
Gross margin down 5.1 points. Operating margin down 13.1 points. Positive free cash flow.

Earnings Call Summary

The company closed its acquisition of Amicus last week and is integrating two therapies for rare genetic disorders. Q1 revenue of 766 million dollars was below guidance due to order timing from strong Q4 orders, but patient demand remains robust with Voxzogo patient growth up 20 percent year over year and new adolescent label for Palynziq driving physician engagement. Management expects Q2 EPS to be only modestly higher than Q1 due to pre-close acquisition costs and revenue timing weighted to later quarters, but pivotal data readouts for Voxzogo in hypochondroplasia and BMN-401 are expected in Q2.

Guidance BioMarin raised full year revenue guidance to 3.825 to 3.925 billion dollars after closing the Amicus acquisition, which adds Galafold and Pombility to their Enzyme Therapies portfolio. They expect 20 percent revenue growth in 2026 at the midpoint, with about 55 percent of annual revenue coming in the second half of the year due to order timing and eight months of Amicus product sales beginning in May.

Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.

Insider Buying and Selling at BioMarin Pharmaceutical Inc.

Recent insider transactions show selling activity at BioMarin. Gregory R. Friberg, an officer, sold 6,326 shares at an average price of $60.38 on February 26, 2026, totaling about $381,937. Charles Greg Guyer, the Chief Technology Officer, sold 16,486 shares at $60.46 on March 11, 2026, worth approximately $996,744. Gregory R. Friberg sold another 3,281 shares at $53.85 on May 7, 2026, valued at about $176,682, and George Eric Davis, another officer, sold 17,557 shares at $66.28 on September 2, 2026, totaling around $1.16 million.

Analysts Set New Price Targets

In addition to Barclays, several analysts have recently made calls on BioMarin. On August 31, 2026, Jefferies maintained a Buy rating with a target of $105.0, slightly up from $104.0. HC Wainwright & Co. also maintained a Neutral rating with a target increase from $59.0 to $60.0. Piper Sandler reiterated its Overweight rating with a target increase from $88.0 to $90.0 on September 1, 2026.

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a biotechnology company based in San Rafael, CA. It develops and commercializes therapies aimed at treating rare diseases and medical conditions. This focus on niche markets positions BioMarin uniquely within the healthcare sector, making its performance closely watched by investors.

Bottom Line

Investors should watch for BioMarin's upcoming earnings report on October 26, 2026, which will provide insights into the company's financial health and growth trajectory. Barclays' reiteration of its Overweight rating and the new price target could influence market sentiment in the coming weeks.